Samsung's JB Park reveals why the company has not yet launched Trifold smartphone
officially confirmed the existence of its trifold smartphone last month, announcing plans to launch the device by the end of this year. A top executive has now offered insight into why the South Korean tech giant deliberately delayed the commercial release. According to
JB Park
, president and CEO, Samsung Southwest Asia, the company focused on a more fundamental question before rushing to market: whether consumers would truly see the value in such a product.
'The question is, will we tri-fold it, quadruple it, or why do we need to do it? The first question is, why do we need it? If you unfold the tri-fold or quadruple fold, how big will it be? And why do we need to roll it or fold it? I think the fundamental question is, will consumers see the value of it?' Park told The Times of India Tech in a response to a question about the next evolution of the company's
foldable smartphones
.
Park suggested that the decision to hold back on a trifold smartphone is a strategic one, aimed at avoiding a bulky form factor that doesn't significantly benefit the user.
'If you can carry a laptop, do you want to fold a laptop to make it smaller? If you have a tablet, do you want to fold your tablet to make it smaller?' Park questioned.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Treatment That Might Help You Against Knee Pain (Search Now)
Knee Pain Treatment | Search Ads
Undo
'I think it really doesn't give a benefit because it becomes so bulky. Yes, the technology is available, but we don't market it.
We don't commercialise it, because I don't think it makes sense
,' he explained, soon after the company launched the Galaxy Z Fold7, Galaxy Z Flip7 and Galaxy Z Flip 6SE smartphones at the Galaxy Unpacked event in New York.
JB Park on where does AI 'unfolds' in the next era
When asked about the next-generation AI features that customers can expect in smartphones in the coming months and in distant future, Park said that Samsung believes will be defined by artificial intelligence (AI). The representative stated that the future of AI will be about on-device AI that is independent of the cloud but can connect to it to perform complex tasks.
"Tomorrow, I think it's more of how people are using the AI. Whether it's productivity or coding, engineering or in your academic research when you have to write your term paper, the AI kicks in," he explained. This advanced, on-device AI will be powerful enough to guide users toward better solutions, effectively replacing a laptop for many tasks.
Notably, Samsung's newest foldable smartphones – Galaxy Z Fold7 and Galaxy Z Flip7 – feature a string of AI tools and features that align with the company's broader focus on delivering a smarter and more meaningful user experience. The company partnered with Google to power Galaxy AI features.
Park pointed to a specific example for the Indian market, where its AI could assist with real-time, simultaneous translation for the country's many different dialects.
'That's where I think it will assist on not only in translation. Like in India, you have so many dialects that you need someone to interpret. Tomorrow, it will all be done simultaneously on the devices. So you don't have to memorise things. You don't have to have an opinion of a lawyer or doctor. You just can have a massive intelligence that's connected on your device to a cloud that can guide you to a better solution,' Park noted.
The executive concluded by saying that as the AI technology evolves, Samsung will be the pioneer in moving towards that direction.
Samsung Galaxy Z Fold7: 7 UNMATCHED Features No Other Foldable Has!
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
41 minutes ago
- Time of India
Govt aims to accelerate pace of highway construction to 100 km/day: Gadkari
Union Road Transport and Highways Minister Nitin Gadkari on Friday said the government's aim is to accelerate the pace of highway construction to 100 km a day from 38 km/day at present. Speaking at the Business Today India@100 event, Gadkari said so far this year, the road ministry has awarded highways projects worth Rs 2.5 lakh crore, and by March next year, it will award highways projects worth Rs 10 lakh crore. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program "Currently, the pace of National Highways construction in India is 38 km/day. We aim to accelerate the pace of highway construction to 100 km a day. This is our target, whether it will happen next year, I can not say," he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Could Be the Best Time to Trade Gold in 5 Years IC Markets Learn More Undo The ministry constructed 10,660 km of national highways in 2024-25, 12,349 km in 2023-24 and 10,331 km in 2022-23. Responding to the growing concern over social media about E20, rolled out by the government, is damaging the vehicle and there is no reduction in fuel cost, Gadkari rejected the claim, saying that the petroleum sector is lobbying against this move. Live Events "I challenge, if anyone has faced difficulty in his vehicle on account of mixing of ethanol in petrol," Gadkari, who is known for his frank views, said. The minister further said that Pune-based Automotive Research Association of India (ARAI) conducts trials and comes up with reports before the government takes a call on ethanol blending. Currently, Indian vehicles can run on E20 petrol with minor changes to the engine to prevent corrosion and other issues. In 2023, Prime Minister Narendra Modi launched petrol blended with 20 per cent ethanol. The Indian government will introduce guidelines for 27 per cent ethanol blending in petrol by the end of August. Ethanol, which can be produced from sugarcane, broken rice and other agricultural products, is expected to help reduce India's dependence on foreign oil. India is currently the world's third-largest oil consumer and imports about 88 per cent of its crude oil requirements, making it vulnerable to geopolitical vagaries that can impact crude prices. Gadkari reiterated that his aim is to make India's automobile industry number one in the world. The size of the Indian automobile industry is now Rs 22 lakh crore. Presently, the size of the US automobile industry is Rs 78 lakh crore, followed by China (Rs 47 lakh crore) and India (Rs 22 lakh crore). According to the minister, the automobile industry has created 4.5 crore jobs till now -- the highest in the country. Gadkari also said the days are not far away when prices of electric vehicles (EVs) will be less than those of petrol vehicles in the country within six months. The minister also said India's logistics cost will come down to 9 per cent by December this year. In China, the logistics cost is 8 per cent, and in the US and European countries, it is 12 per cent, the minister said. Gadkari also emphasised the need to increase the productivity of the agriculture sector.
Time of India
an hour ago
- Time of India
'Emperor of Maladies' v 'Maharaja of Tariffs'
TOI correspondent from Washington: Dubbing India the "Maharaja of Tariffs," US Donald Trump's minions are unloading on New Delhi amid growing signs that beyond the trade dispute, the MAGA supremo is jettisoning stated US objective voiced by three previous presidents of supporting the rise of India as a counterweight to China. In scabrous remarks to reporters, Trump's trade counselor Peter Navarro on Thursday accused India of using US dollars to buy oil from Russia, which in turn "uses those dollars from India to finance weapons to kill Ukrainians and American taxpayers are being asked to pay for weapons to defend Ukraine from Russian weapons bought with US dollars from India." "This has to stop. This math doesn't work. The president understands the connection between economic and national security. So that was the crux of the matter," Navarro said, rationalizing the 50 percent tariff on Indian exports. Navarro's dodgy logic was called out by reporters who asked why in that case Beijing, which buys more Russian oil than India does, was not being penalized, leading him to make a key admission: The US is under the cosh when it comes to China and "we don't want to hurt ourselves" with higher tariffs. "As the boss says, we'll see what happens. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Back Pain Treatments That Might Surprise You! Back Pain Treatment | Search Ads Undo Remember, we already have over 50% tariffs on China, okay?" Navarro said, leaving a small opening for a resolution. Navarro, a convicted felon who served time in prison and faked quotes for his book from a fictitious expert named "Ron Vara" (an anagram of his own name), is known as Trump's "trade whisperer" who echoes his boss' faith in tariffs. But he went way over the top alleging "we send a lot of dollars to India to buy their goods on unfair trade terms... India then uses US dollars to buy Russian oil." A knowledgeable Indian analyst who declined to go on record rubbished the "absurd" claim, saying India earns US dollars through "legitimate exports, not charity." Furthermore, India used those dollars to buy American products and goods, including armaments, he added, pointing out that the US is India's top trading partner, while Russia only ranks fourth. "Not to forget India buys Russian oil with a mix of currencies including rupees," he noted. New Delhi has also contested Trump's claims that India hits the US with some of the highest tariffs in the world, pointing out that he makes similar claims against Canada, even as India has brought down tariffs on a range of US exports. As for charges of non-tariff barriers imposed by India, officials say the US too has similar barriers, such as Sanitary and Phytosanitary (SPS) measures, to protect its domestic industry. While some analysts are positing that Trump's crackdown on India is a negotiating tactic, matters appear to have gone beyond that with Trump officials implicitly characterising India as a national security threat. India's quick responses, including outreach to Russia, China, and Brazil, has also triggered concerns in the strategic community that the Trump White House is alienating New Delhi and pushing it firmly into the BRICS group which the US President is trying to dismantle with a divide and rule approach. Notably, Trump has taken punitive measures against the two democracies in the group while holding fire against China. On Friday, a day after he talked to Brazil's President Lula, a post by PM Modi on X spoke of "a good and detailed conversation with my friend President Putin," and conspicuously said they "reviewed the progress in our bilateral agenda, and reaffirmed our commitment to further deepen the India-Russia Special and Privileged Strategic Partnership." "I look forward to hosting President Putin in India later this year," the post concluded in an implicit rebuff to Trump. The US President was expected to visit India in September-November window for the Quad summit -- a trip that looks doomed unless there is a swift change in the situation. Stay informed with the latest business news, updates on bank holidays , public holidays , current gold rate and silver price .
Time of India
an hour ago
- Time of India
Biocon sees GLP-1 weight-loss therapy as a future growth driver
Biocon will continue to deepen its push in the insulin business, even as the biopharmaceutical company will have GLP-1 weight-loss therapy as one of the key focus areas in its future growth strategy, Shreehas Tambe, chief executive of Biocon Biologics, told ET on Friday. Leveraging decades of experience in insulin, the Bengaluru-based company aims to gain an edge over rivals in the race for copycats of GLP-1 drugs, which are gaining popularity as an effective treatment for glucose control as well as weight management. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Biocon has completed bioequivalence studies in India for semaglutide , a GLP-1 drug, and is progressing to Phase-III trials, which it expects to conclude by the end of calendar year 2026. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 'Subsequent regulatory approval is anticipated in CY 2027, after which we will launch the product in India through a partner,' said Tambe, who is also the managing director of the biosimilar and biologics subsidiary of Biocon. Novo Nordisk's blockbuster weight-loss drug semaglutide (branded Wegovy) will go off patent in India in March. Live Events On being asked about the disruption in the diabetes drug segment due to the inroads by GLP-1 products, Tambe said: 'The disruption (due to GLP-1) is complementary to insulin. We are bullish on both insulin and GLP-1.' 'The originators who brought GLP1s are the insulin companies, and they were able to do that because it is synergistic. Synergy not just in terms of the therapy area but also in terms of operations, touchpoints for prescribers, healthcare givers and customers,' said Tambe, who is also the company's managing director. Biocon has both biosimilar insulins and GLP-1 peptides that mimic a naturally occurring gut hormone that controls sugar levels and appetite. 'That is what differentiates us from the rest,' he said. 'Having been close to the market will give an advantage because it requires a lot of expertise as the drug is in the form of an injectable, given in a device, is a chronic treatment and hence requires a long-term relationship with patients who need to be trained on those devices,' said Tambe. 'All of these we have been able to do with our insulins in the past several years in 80-plus countries that is why we feel confident and we are developing both portfolios that are complementary to each other.' The company got US Food and Drug Administration approval for insulin aspart, its second interchangeable biosimilar insulin, deepening its presence in the US insulin market. 'The US FDA approval of Kirsty (biosimilar aspart) builds on the strong foundation established with Semglee (biosimilar insulin glargine), enabling us to offer patients the full range of affordable short- and long-acting insulin therapies,' he said. 'Insulin aspart we will enter by the end of this fiscal,' he said. The company got approval for diabetes drug liraglutide in India in June. The drug, used in treating type-2 diabetes, has already launched in the UK and the EU. 'We are working towards expeditiously launching the drug product through our commercialisation partners in India,' said Tambe. 'The biggest concern for the year ahead is external risks to the business, such as potential tariff and geopolitical headwinds. Some of these things are not in our control but that is the biggest concern for the whole industry too,' he said.
